To include your compound in the COVID-19 Resource Center, submit it here.

Shire Phase III interim Fosrenol results

Shire (LSE:SHP; SHPGY) reported interim results showing that after one year of a two-year, 1,203-patient U.S. Phase III study to treat

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE